Compare Stocks: CLLS, VALN, CBIO, and ALLO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.67	$1.90	$1.04 ▼ $4.46	$590.79M	0.47	5.25 million shs	7.75 million shs
CBIO Crescent Biopharma	$14.24 +0.4%	$17.10	$8.72 ▼ $27.41	$610.65M	1.24	486,226 shs	568,819 shs
CLLS Cellectis	$1.43 -0.7%	$2.77	$1.25 ▼ $5.48	$156.53M	2.92	182,504 shs	68,784 shs
VALN Valneva	$6.22 -2.0%	$6.07	$4.75 ▼ $12.23	$625.30M	1.67	30,345 shs	51,758 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	0.00%	-3.47%	-23.04%	-21.60%	+35.77%
CBIO Crescent Biopharma	+0.35%	-15.09%	-16.24%	-22.96%	+9.71%
CLLS Cellectis	-0.69%	-2.05%	-58.19%	-49.47%	-58.79%
VALN Valneva	-2.05%	-5.33%	-8.26%	+19.85%	-39.61%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.67	$1.90	$1.04 ▼ $4.46	$590.79M	0.47	5.25 million shs	7.75 million shs
CBIO Crescent Biopharma	$14.24 +0.4%	$17.10	$8.72 ▼ $27.41	$610.65M	1.24	486,226 shs	568,819 shs
CLLS Cellectis	$1.43 -0.7%	$2.77	$1.25 ▼ $5.48	$156.53M	2.92	182,504 shs	68,784 shs
VALN Valneva	$6.22 -2.0%	$6.07	$4.75 ▼ $12.23	$625.30M	1.67	30,345 shs	51,758 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	0.00%	-3.47%	-23.04%	-21.60%	+35.77%
CBIO Crescent Biopharma	+0.35%	-15.09%	-16.24%	-22.96%	+9.71%
CLLS Cellectis	-0.69%	-2.05%	-58.19%	-49.47%	-58.79%
VALN Valneva	-2.05%	-5.33%	-8.26%	+19.85%	-39.61%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.69	Moderate Buy	$8.30	397.01% Upside
CBIO Crescent Biopharma	2.83	Moderate Buy	$29.60	107.87% Upside
CLLS Cellectis	2.29	Hold	$5.46	281.82% Upside
VALN Valneva	1.67	Reduce	$9.30	49.52% Upside

Current Analyst Ratings Breakdown

Latest CLLS, VALN, CBIO, and ALLO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	CLLS Cellectis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/16/2026	CLLS Cellectis	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Underweight	$9.00 ➝ $1.30
9/15/2026	CLLS Cellectis	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$10.00 ➝ $8.00
9/15/2026	CLLS Cellectis	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$4.00 ➝ $3.00
9/15/2026	CLLS Cellectis	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
9/14/2026	VALN Valneva	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/14/2026	CBIO Crescent Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$27.00
9/9/2026	ALLO Allogene Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	CBIO Crescent Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$27.00
8/26/2026	ALLO Allogene Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/24/2026	CBIO Crescent Biopharma	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 9/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$20K	28,848.42	N/A	N/A	$1.30 per share	1.28
CBIO Crescent Biopharma	$10.84M	48.79	N/A	N/A	$14.32 per share	0.99
CLLS Cellectis	$79.59M	1.80	N/A	N/A	$0.76 per share	1.88
VALN Valneva	$197.56M	2.99	N/A	N/A	$1.39 per share	4.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$190.89M	-$0.67	N/A	N/A	N/A	N/A	-50.04%	-36.74%	11/5/2026 (Estimated)
CBIO Crescent Biopharma	-$153.94M	-$6.72	N/A	N/A	N/A	N/A	-101.50%	-86.86%	11/5/2026 (Estimated)
CLLS Cellectis	-$67.59M	-$0.65	N/A	N/A	N/A	-102.34%	-94.19%	-21.34%	11/13/2026 (Estimated)
VALN Valneva	-$130.33M	-$2.11	N/A	14.14	N/A	-110.33%	-153.20%	-39.50%	11/19/2026 (Estimated)

Latest CLLS, VALN, CBIO, and ALLO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	VALN Valneva	-$0.1886	-$0.40	-$0.2114	-$0.38	$44.17 million	$39.37 million
8/12/2026	Q2 2026	ALLO Allogene Therapeutics	-$0.1714	-$0.13	+$0.0414	-$0.13	$0.00 million	$4.64 million
8/7/2026	H1 2026	CLLS Cellectis	-$0.2630	-$0.22	+$0.0430	-$0.22	$11.05 million	$6.90 million
7/30/2026	Q2 2026	CBIO Crescent Biopharma	-$0.7357	-$0.74	-$0.0043	-$0.74	$0.36 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
CBIO Crescent Biopharma	N/A	N/A	N/A	N/A	N/A
CLLS Cellectis	N/A	N/A	N/A	N/A	N/A
VALN Valneva	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	10.72	10.72
CBIO Crescent Biopharma	N/A	9.66	9.66
CLLS Cellectis	1.61	1.37	1.37
VALN Valneva	2.04	2.16	1.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
CBIO Crescent Biopharma	75.19%
CLLS Cellectis	63.90%
VALN Valneva	11.39%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
CBIO Crescent Biopharma	24.84%
CLLS Cellectis	16.41%
VALN Valneva	14.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	152	345.49 million	299.89 million	Optionable
CBIO Crescent Biopharma	44	37.14 million	27.92 million	No Data
CLLS Cellectis	229	100.34 million	83.87 million	Optionable
VALN Valneva	674	94.89 million	80.74 million	Not Optionable

CLLS, VALN, CBIO, and ALLO Headlines

Recent News About These Companies

Analyzing Valneva (NASDAQ:VALN) and Septerna (NASDAQ:SEPN)

September 24 at 4:00 AM | defenseworld.netD

Football fundraiser collects £2k for Livingston charity Team Jak Foundation

September 22 at 2:37 PM | msn.com

Valneva's Lyme Shot Nears EU Verdict as Pipeline Readouts and Cost Cuts Converge

September 21, 2026 | ad-hoc-news.deA

Pfizer (PFE), Valneva (VALN) Lyme Vaccine Moves to EMA Review Despite Phase 3 Caveat

September 15, 2026 | insidermonkey.com

Valneva Aktie: Umsatz bricht um 33 Prozent ein

September 9, 2026 | boerse-express.comB

Valneva Aktie: Verkauf von Nantes vereinbart

September 6, 2026 | boerse-express.comB

Valneva (NASDAQ:VALN) Trading Up 7.1% - Time to Buy?

September 2, 2026 | marketbeat.com

Valneva (NASDAQ:VALN) Shares Gap Up - Time to Buy?

September 1, 2026 | marketbeat.com

Potential Moderna-style share surge? Takeover candidates Evotec, Valneva and Vidac Pharma in focus — analysts bullish

September 1, 2026 | msn.com

Valneva's Property Sale Buys Breathing Room as Travel-Vaccine Demand Sours

August 30, 2026 | ad-hoc-news.deA

Valneva's High-Wire Act: Can Cost Cuts and a Pivotal EMA Review Bridge the Gap to 2026?

August 29, 2026 | ad-hoc-news.deA

Answers to 3 questions about a potential Lyme vaccine

August 28, 2026 | msn.com

Valneva's Regulatory Tailwind Collides With a Deepening Loss Profile

August 24, 2026 | ad-hoc-news.deA

Valneva's Analyst Divide Widens as EMA Review Puts Statistical Questions in the Spotlight

August 20, 2026 | ad-hoc-news.deA

Valneva (VALN) Q2 2026 Earnings Call Transcript

August 20, 2026 | finance.yahoo.com

EMA validates marketing authorisation application of Pfizer & Valneva’s PF-07307405, a 6-valent OspA-based Lyme disease vaccine

August 17, 2026 | pharmabiz.comP

EMA validates Pfizer and Valneva’s Lyme disease vaccine

August 17, 2026 | msn.com

Pfizer, Valneva Lyme vaccine starts review in Europe

August 15, 2026 | pharmaphorum.comP

Valneva Shares Climb After Lyme Disease Vaccine Receives EMA Application Acceptance

August 15, 2026 | marketwatch.com

Update: Valneva Shares Gain as Lyme Vaccine Candidate Gets EMA Review

August 15, 2026 | finance.yahoo.com

A Lyme disease vaccine may finally be on the way. Why did it take so long?

August 14, 2026 | nationalpost.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLLS, VALN, CBIO, and ALLO Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.67 0.00 (0.00%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$1.70 +0.03 (+1.50%)

As of 04:52 AM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Crescent Biopharma NASDAQ:CBIO

$14.24 +0.05 (+0.35%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$14.23 -0.01 (-0.04%)

As of 09/24/2026 04:10 PM Eastern

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Cellectis NASDAQ:CLLS

$1.43 -0.01 (-0.69%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$1.43 +0.00 (+0.07%)

As of 04:00 AM Eastern

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Valneva NASDAQ:VALN

$6.22 -0.13 (-2.05%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$6.13 -0.09 (-1.38%)

As of 05:05 AM Eastern

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CLLS, VALN, CBIO, and ALLO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CLLS, VALN, CBIO, and ALLO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CLLS, VALN, CBIO, and ALLO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLLS, VALN, CBIO, and ALLO Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

Crescent Biopharma NASDAQ:CBIO

Cellectis NASDAQ:CLLS

Valneva NASDAQ:VALN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CLLS, VALN, CBIO, and ALLO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CLLS, VALN, CBIO, and ALLO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CLLS, VALN, CBIO, and ALLO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLLS, VALN, CBIO, and ALLO Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

Crescent Biopharma NASDAQ:CBIO

Cellectis NASDAQ:CLLS

Valneva NASDAQ:VALN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools